Indication-Based Pricing Gaining Support in UK
Sydney Otomancek2020-11-11T12:00:49-05:00November 11th, 2020|Categories: Featured, Industry News|Tags: HEOR, multi-indication pricing (MIP), pharma. UK drug costs, pricing|
A cross-sector expert panel to improve patient access to innovative cancer medicines in the UK recommended that drug prices should [...]
Receive essential insights, resources and content direct to your inbox!
Hit subscribe to stay informed!
Advertisement
Latest News
Featured Webinars
Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters
Tuesday, December 5, 2023
Sponsor: ICON
EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025
Friday, November 10, 2023
Sponsor: OpenHealth
Cell & Gene Therapies – Beginning with the End in Mind
Thursday, November 2, 2023
Sponsor: Magnolia Market Access
Categories
Artificial Intelligence
Careers
Clinical Trials
Cost Effectiveness
Data Analytics & Syndicated Reports
Healthcare Financing
Health Databases
Health Equity
Health Policy
Health Tech Assessment
Integrated Evidence Assessment & Planning
Market Access
Medical Affairs
Patient Outcomes & Engagement
Pricing & Reimbursement
Real World Data
Real World Evidence
Value Assessment
Value Communication